Furthermore, administration of small, repeated doses of 5-HT1A receptor agonist buspirone was able to attenuate graft-induced dyskinesias possibly by attenuating the abnormal serotonin terminal-derived dopamine release. Here, HTR1A is linked to Dyskinesia.